Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state

References

• Marley SB, Gordon MY. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. Clin Sci (Lond) 2005;109:13–25.
   PubMed Web of Science ®Google Scholar
• Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657–667.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med;2010:362:2260–2270.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med;2010:362:2251–2259.
   PubMed Web of Science ®Google Scholar
• Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. Punish the parent not the progeny. Blood 2005;105:1862–1866.
   PubMed Web of Science ®Google Scholar
• La Rosee P, Hochhaus A. Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia. Curr Opin Hematol 2010;17:91–96.
   PubMed Web of Science ®Google Scholar
• Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128–2137.
   PubMed Web of Science ®Google Scholar
• Griswold IJ, MacPartlin M, Bumm T, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006;26:6082–6093.
   PubMed Web of Science ®Google Scholar
• Skaggs BJ, Gorre ME, Ryvkin A, et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA 2006;103:19466–19471.
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–4109.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806–4813.
   PubMed Web of Science ®Google Scholar
• Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005;103:1659–1669.
   PubMed Web of Science ®Google Scholar
• Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2006;103:6688–6693.
   PubMed Web of Science ®Google Scholar
• Wendel HG, de Stanchina E, Cepero E, et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA 2006;103:7444–7449.
   PubMed Web of Science ®Google Scholar
• Miething C, Grundler R, Mugler C, et al. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proc Natl Acad Sci USA 2007;104:4594–4599.
   PubMed Web of Science ®Google Scholar
• Kim TD, Turkmen S, Schwarz M, et al. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica 2010;95:582–588.
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:671–684, x.
   PubMed Web of Science ®Google Scholar
• Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2007;26:11–20.
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach T, Hiddemann W, Schnittger S, Kern W, Schoch C. Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet 2005;157:53–61.
   PubMed Web of Science ®Google Scholar
• Brazma D, Grace C, Howard J, et al. Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Genes Chromosomes Cancer 2007;46:1039–1050.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, De Melo VA, Fiegler H, et al. Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis. Leukemia 2008;22:1806–1807.
   PubMed Web of Science ®Google Scholar
• Jiang X, Saw KM, Eaves A, Eaves C. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007;99:680–693.
   PubMed Web of Science ®Google Scholar
• Sorel N, Bonnet ML, Guillier M, Guilhot F, Brizard A, Turhan AG. Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun 2004;323:728–730.
   PubMed Web of Science ®Google Scholar
• Chu S, Xu H, Shah NP, et al. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093–2098.
   PubMed Web of Science ®Google Scholar
• Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002;107:76–94.
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319–325.
   PubMed Web of Science ®Google Scholar
• Skorski T. BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts. Leuk Lymphoma 2008;49:610–614.
   PubMed Web of Science ®Google Scholar
• Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 2006;108:319–327.
   PubMed Web of Science ®Google Scholar
• Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 2004;104:3746–3753.
   PubMed Web of Science ®Google Scholar
• Deluche L, Joha S, Corm S, et al. Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression? Genes Chromosomes Cancer 2008;47:1110–1117.
   PubMed Web of Science ®Google Scholar
• Fabarius A, Haferlach C, Muller MC, et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007;92:834–837.
   PubMed Web of Science ®Google Scholar
• Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007;110:4005–4011.
   PubMed Web of Science ®Google Scholar
• Haferlach C, Bacher U, Schnittger S, Weiss T, Kern W, Haferlach T. Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment. Leukemia 2010;24:638–640.
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 2006;107:4532–4539.
   PubMed Web of Science ®Google Scholar
• Holtz MS, Forman SJ, Bhatia R. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli. Leukemia 2005;19:1034–1041.
   PubMed Web of Science ®Google Scholar
• Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99:3792–3800.
   PubMed Web of Science ®Google Scholar
• Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007;109:4016–4019.
   PubMed Web of Science ®Google Scholar
• Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res 2008;68:9624–9633.
   PubMed Web of Science ®Google Scholar
• Jorgensen HG, Copland M, Allan EK, et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006;12:626–633.
   PubMed Web of Science ®Google Scholar
• Wertheim JA, Forsythe K, Druker BJ, Hammer D, Boettiger D, Pear WS. BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood 2002;99:4122–4130.
   PubMed Web of Science ®Google Scholar
• Fabarius A, Giehl M, Frank O, et al. Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 2005;19:1573–1578.
   PubMed Web of Science ®Google Scholar
• Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007;117:2562–2569.
   PubMed Web of Science ®Google Scholar
• Bertram JS. The molecular biology of cancer. Mol Aspects Med 2000;21:167–223.
   PubMedGoogle Scholar
• Schar P. Spontaneous DNA damage, genome instability, and cancer–when DNA replication escapes control. Cell 2001;104:329–332.
   PubMed Web of Science ®Google Scholar
• Hendry JH. Genomic instability: potential contributions to tumour and normal tissue response, and second tumours, after radiotherapy. Radiother Oncol 2001;59:117–126.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001;477:7–21.
   PubMed Web of Science ®Google Scholar
• Moses RE. DNA damage processing defects and disease. Annu Rev Genomics Hum Genet 2001;2:41–68.
   PubMed Web of Science ®Google Scholar
• Vaish M, Mittal B. DNA mismatch repair, microsatellite instability and cancer. Indian J Exp Biol 2002;40:989–994.
   PubMedGoogle Scholar
• Gutteridge JM, Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. Ann NY Acad Sci 2000;899:136–147.
   PubMed Web of Science ®Google Scholar
• Lu AL, Li X, Gu Y, Wright PM, Chang DY. Repair of oxidative DNA damage: mechanisms and functions. Cell Biochem Biophys 2001;35:141–170.
   PubMed Web of Science ®Google Scholar
• Cramer K, Nieborowska-Skorska M, Koptyra M, et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res 2008;68:6884–6888.
   PubMed Web of Science ®Google Scholar
• Sattler M, Verma S, Shrikhande G, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem 2000;275:24273–24278.
   PubMed Web of Science ®Google Scholar
• Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway. Leukemia 2009;23:1432–1440.
   PubMed Web of Science ®Google Scholar
• Beckman KB, Ames BN. Oxidative decay of DNA. J Biol Chem 1997;272:19633–19636.
   PubMed Web of Science ®Google Scholar
• Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 2008;22:1969–1972.
   PubMed Web of Science ®Google Scholar
• Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002;511:145–178.
   PubMed Web of Science ®Google Scholar
• Slupphaug G, Kavli B, Krokan HE. The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res 2003;531:231–251.
   PubMed Web of Science ®Google Scholar
• Mazurek A, Berardini M, Fishel R. Activation of human MutS homologs by 8-oxo-guanine DNA damage. J Biol Chem 2002;277:8260–8266.
   PubMed Web of Science ®Google Scholar
• Pabst T, Schwaller J, Bellomo MJ, et al. Frequent clonal loss of heterozygosity but scarcity of microsatellite instability at chromosomal breakpoint cluster regions in adult leukemias. Blood 1996;88:1026–1034.
   PubMed Web of Science ®Google Scholar
• Wada C, Shionoya S, Fujino Y, et al. Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Blood 1994;83:3449–3456.
   PubMed Web of Science ®Google Scholar
• Mori N, Takeuchi S, Tasaka T, et al. Absence of microsatellite instability during the progression of chronic myelocytic leukemia. Leukemia 1997;11:151–152.
   PubMed Web of Science ®Google Scholar
• Silly H, Chase A, Mills KI, et al. No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis. Leukemia 1994;8:1923–1928.
   PubMed Web of Science ®Google Scholar
• Stoklosa T, Poplawski T, Koptyra M, et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res 2008;68:2576–2580.
   PubMed Web of Science ®Google Scholar
• Kanaar R, Hoeijmakers JH, van Gent DC. Molecular mechanisms of DNA double strand break repair. Trends Cell Biol 1998;8:483–489.
   PubMed Web of Science ®Google Scholar
• Kowalczykowski SC, Dixon DA, Eggleston AK, Lauder SD, Rehrauer WM. Biochemistry of homologous recombination in Escherichia coli. Microbiol Rev 1994;58:401–465.
   PubMedGoogle Scholar
• Shinohara A, Ogawa T. Homologous recombination and the roles of double-strand breaks. Trends Biochem Sci 1995;20:387–391.
   PubMed Web of Science ®Google Scholar
• Richardson C, Jasin M. Coupled homologous and nonhomologous repair of a double-strand break preserves genomic integrity in mammalian cells. Mol Cell Biol 2000;20:9068–9075.
   PubMed Web of Science ®Google Scholar
• Jasin M. Chromosome breaks and genomic instability. Cancer Invest 2000;18:78–86.
   PubMed Web of Science ®Google Scholar
• Van Dyck E, Stasiak AZ, Stasiak A, West SC. Visualization of recombination intermediates produced by RAD52-mediated single-strand annealing. EMBO Rep 2001;2:905–909.
   PubMed Web of Science ®Google Scholar
• Ivanov EL, Sugawara N, Fishman-Lobell J, Haber JE. Genetic requirements for the single-strand annealing pathway of double-strand break repair in Saccharomyces cerevisiae. Genetics 1996;142:693–704.
   PubMed Web of Science ®Google Scholar
• Slupianek A, Nowicki MO, Koptyra M, Skorski T. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst) 2006;5:243–250.
   PubMed Web of Science ®Google Scholar
• Gaymes TJ, Mufti GJ, Rassool FV. Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70/86 heterodimer. Cancer Res 2002;62:2791–2797.
   PubMed Web of Science ®Google Scholar
• Fernandes MS, Reddy MM, Gonneville JR, et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009;114:1813–1819.
   PubMed Web of Science ®Google Scholar
• Slupianek A, Schmutte C, Tombline G, et al. BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell 2001;8:795–806.
   PubMed Web of Science ®Google Scholar
• Slupianek A, Hoser G, Majsterek I, et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol 2002;22:4189–4201.
   PubMed Web of Science ®Google Scholar